Monette Cotreau

2.2k total citations
52 papers, 1.8k citations indexed

About

Monette Cotreau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Monette Cotreau has authored 52 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Monette Cotreau's work include Renal cell carcinoma treatment (11 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Monette Cotreau is often cited by papers focused on Renal cell carcinoma treatment (11 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Monette Cotreau collaborates with scholars based in United States, Netherlands and Canada. Monette Cotreau's co-authors include David J. Greenblatt, Lisa L. von Moltke, Jerold S. Harmatz, Gary B. Kaplan, Richard I. Shader, Bruce L. Ehrenberg, Jill Goddard, Andrew Strahs, W Horst and Sheldon Preskorn and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Monette Cotreau

51 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Monette Cotreau United States	19	460	359	312	309	254	52	1.8k
Masayoshi Soma Japan	34	1.4k 3.0×	249 0.7×	202 0.6×	346 1.1×	319 1.3×	256	4.6k
Anthony Lee United States	28	1.2k 2.5×	456 1.3×	441 1.4×	116 0.4×	226 0.9×	119	3.3k
Daniel F. Carr United Kingdom	24	252 0.5×	213 0.6×	263 0.8×	308 1.0×	76 0.3×	67	1.5k
Cyril Mamotte Australia	26	798 1.7×	157 0.4×	201 0.6×	676 2.2×	95 0.4×	67	3.4k
Bo Gao China	30	897 1.9×	782 2.2×	144 0.5×	219 0.7×	89 0.4×	77	3.1k
Vita Dolžan Slovenia	33	1.3k 2.8×	362 1.0×	446 1.4×	168 0.5×	394 1.6×	210	3.7k
Sheng‐Ming Dai China	31	1.2k 2.5×	248 0.7×	189 0.6×	396 1.3×	226 0.9×	91	3.3k
Hiroko Shimizu Japan	30	1.5k 3.2×	448 1.2×	109 0.3×	235 0.8×	228 0.9×	99	2.8k
Jane F Armstrong United Kingdom	19	2.2k 4.8×	604 1.7×	177 0.6×	326 1.1×	373 1.5×	30	4.3k
Zongfang Li China	29	873 1.9×	377 1.1×	108 0.3×	331 1.1×	139 0.5×	96	2.3k

Countries citing papers authored by Monette Cotreau

Since Specialization

Citations

This map shows the geographic impact of Monette Cotreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monette Cotreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monette Cotreau more than expected).

Fields of papers citing papers by Monette Cotreau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monette Cotreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monette Cotreau. The network helps show where Monette Cotreau may publish in the future.

Co-authorship network of co-authors of Monette Cotreau

This figure shows the co-authorship network connecting the top 25 collaborators of Monette Cotreau. A scholar is included among the top collaborators of Monette Cotreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monette Cotreau. Monette Cotreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Minchom, Anna, Edward G. Garmey, Lukas Makris, et al.. (2024). 680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies. Annals of Oncology. 35. S530–S530. 1 indexed citations

Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2014). Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer. 111(2). 272–280. 37 indexed citations

Cotreau, Monette, et al.. (2013). The effect of food on the pharmacokinetics of tivozanib hydrochloride. Clinical Pharmacology in Drug Development. 3(2). 158–162. 5 indexed citations

Eskens, Ferry A.L.M., Corina N.A.M. Oldenhuis, Walter J. Loos, et al.. (2012). Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.. Journal of Clinical Oncology. 30(15_suppl). 4132–4132. 3 indexed citations

Cotreau, Monette, et al.. (2012). Absorption, Metabolism, and Excretion of [¹⁴C]‐Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open‐Label, Mass‐Balance Study. Clinical Pharmacology in Drug Development. 1(3). 102–109. 11 indexed citations

Eskens, Ferry A.L.M., Maja J.A. de Jonge, Pankaj Bhargava, et al.. (2011). Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(22). 7156–7163. 89 indexed citations

Oldenhuis, Corina N.A.M., Pankaj Bhargava, Walter J. Loos, et al.. (2010). 370 A phase Ib study of escalating doses of Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitor Tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors. European Journal of Cancer Supplements. 8(7). 117–117. 1 indexed citations

Kelly, Karen, Jimmy J. Hwang, Geoffrey I. Shapiro, et al.. (2010). Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3103–3103. 1 indexed citations

Crabtree, Judy S., Scott A. Jelinsky, Heather A. Harris, et al.. (2009). Comparison of Human and Rat Uterine Leiomyomata: Identification of a Dysregulated Mammalian Target of Rapamycin Pathway. Cancer Research. 69(15). 6171–6178. 83 indexed citations

10.

Bhargava, Pankaj, Dan Laheru, Maximiliano Van Kooten, et al.. (2009). Abstract C31: Phase 1 study of AV-412, a novel irreversible EGFR inhibitor, administered daily in patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). C31–C31. 1 indexed citations

11.

Fishman, Mayer, Sandy Srinivas, Ralph J. Hauke, et al.. (2009). Abstract B60: Combination of tivozanib (AV-951) and temsirolimus in patients with renal cell carcinoma (RCC): Preliminary results from a phase 1 trial. Molecular Cancer Therapeutics. 8(12_Supplement). B60–B60. 2 indexed citations

12.

Eskens, Ferry A.L.M., Maja J.A. de Jonge, Brooke Esteves, et al.. (2008). Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Research. 68(9_Supplement). LB–201. 14 indexed citations

13.

Jelinsky, Scott A., Sung Choe, Judy S. Crabtree, et al.. (2008). Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman. BMC Medical Genomics. 1(1). 27–27. 17 indexed citations

14.

Burczynski, Michael E., Ron Peterson, Natalie C. Twine, et al.. (2006). Molecular Classification of Crohn's Disease and Ulcerative Colitis Patients Using Transcriptional Profiles in Peripheral Blood Mononuclear Cells. Journal of Molecular Diagnostics. 8(1). 51–61. 191 indexed citations

15.

Cotreau, Monette, et al.. (2003). A phase 1, randomized, double-blind, placebo-controlled dose-escalating, safety, tolerability, pharmacokinetic, and pharmacodynamic study of oral recombinant human interleukin eleven (O-rhIl-11) in normal healthy subjects. Gastroenterology. 124(4). A377–A377. 1 indexed citations

16.

Kotegawa, Tsutomu, Bart Laurijssens, Lisa L. von Moltke, et al.. (2002). In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat. Journal of Pharmacology and Experimental Therapeutics. 302(3). 1228–1237. 88 indexed citations

17.

Cotreau, Monette, et al.. (2002). Multiple‐Dose, Safety, Pharmacokinetics, and Pharmacodynamics of a New Selective Estrogen Receptor Modulator, ERA‐923, in Healthy Postmenopausal Women. The Journal of Clinical Pharmacology. 42(2). 157–165. 17 indexed citations

18.

Cotreau, Monette, Lisa L. von Moltke, Margery C. Beinfeld, & David J. Greenblatt. (2000). Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. Journal of Pharmacological and Toxicological Methods. 43(1). 41–54. 42 indexed citations

19.

Moltke, Lisa L. von, et al.. (2000). Unusually Low Clearance of Two CYP3A Substrates, Alprazolam and Trazodone, in a Volunteer Subject with Wild‐Type CYP3A4 Promoter Region. The Journal of Clinical Pharmacology. 40(2). 200–204. 4 indexed citations

20.

Kaplan, Gary B., David J. Greenblatt, Bruce L. Ehrenberg, et al.. (1997). Dose‐Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans. The Journal of Clinical Pharmacology. 37(8). 693–703. 306 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact